Compare WB & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WB | CMPS |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2014 | 2020 |
| Metric | WB | CMPS |
|---|---|---|
| Price | $6.37 | $12.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 16 |
| Target Price | $8.24 | ★ $23.75 |
| AVG Volume (30 Days) | 883.9K | ★ 2.4M |
| Earning Date | 11-17-2026 | 11-03-2026 |
| Dividend Yield | ★ 9.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.11 | N/A |
| Revenue Next Year | $0.78 | N/A |
| P/E Ratio | $5.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.37 | $4.88 |
| 52 Week High | $12.77 | $15.87 |
| Indicator | WB | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 32.11 | 36.87 |
| Support Level | N/A | $11.56 |
| Resistance Level | $6.79 | $14.98 |
| Average True Range (ATR) | 0.10 | 0.75 |
| MACD | 0.02 | -0.29 |
| Stochastic Oscillator | 25.00 | 2.33 |
Weibo Corp is a China-based company that operates a social media platform for people to create, discover and distribute content. The company currently operates and manages its business in two principal business lines globally - advertising and marketing services and value-added services. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The company's main product is the social platform Weibo. It generates a substantial majority of its revenues from online advertising and marketing services.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.